☆ 4.8 Meeting Abstract

Dose response and safety of the daily, oral RIG-I agonist Inarigivir (SB 9200) in treatment naive patients with chronic hepatitis B: results from the 25mg and 50mg cohorts in the ACHIEVE trial

JOURNAL OF HEPATOLOGY (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF HEPATOLOGY
Volume 68, Issue -, Pages S509-S510

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-8278(18)31267-4

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.